Get the SPI Wire

Quince Therapeutics, Inc.

NASDAQ:QNCX
Annual Meeting

of Shareholders

MEETING DATE

10/06/2026
DEF 14A FILED
08/25/2026
PUBLISHED
08/25/2026 12:30 pm
TIME TO PUBLISH
08/27/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:QNCX · CUSIP 22053A107 · CLASS common stock · CIK 0001662774

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

6
FOR
0
AGAINST
0
WITHHOLD
6
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Approval of issuance of shares of our common stock, upon conversion of our Series C Preferred Stock and exercise of the Warrants and Orphai Options, which (a) will represent more than 20% of the shares of common stock outstanding pursuant to Nasdaq Listing Rule 5635(a) and (b) may, together with certain changes to management and our Board, result in the change of control of the Company pursuant to Nasdaq Listing Rule 5635(b)
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Nasdaq Listing Rules require stockholder approval for these issuances and potential change of control.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
Approval of issuance of shares of our common stock, upon conversion of the PIPE Preferred Shares and upon exercise of the PIPE Warrants pursuant to Nasdaq Listing Rule 5635(d)
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states stockholder approval is required under Nasdaq Listing Rule 5635(d).

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
Approval of an amendment to our certificate of incorporation to increase the number of authorized shares of our common stock from 250,000,000 to 275,000,000
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the amendment increases authorized common stock from 250,000,000 to 275,000,000.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
Approval of the 2026 Equity Incentive Plan
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The board approved the 2026 Plan on July 29, 2026, subject to stockholder approval.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
Approval of the 2026 ESPP
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The board approved the 2026 ESPP on July 30, 2026, subject to stockholder approval.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
Approval of the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1, 2 and/or 3
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states adjournment may be used to continue soliciting votes for Proposals 1, 2 and 3.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

1d0147959dcbb389d9b631db6da3d4605e77ea48805e2c5086a903365dc6314c

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates